Biomedical Research in the 21st Century: Multiple Challenges in Resolving Reproducibility Issues

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Business

• Identifiers
  DOI 10.1016/B978-0-12-804725-5.00006-9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• On Political Correctness

  2019cited by this paper
• PPARδ Promotes Running Endurance by Preserving Glucose.

  2017cited by this paper
• The academic-industrial complex: navigating the translational and cultural divide.

  2017cited by this paper
• Enhancing reproducibility: Failures from Reproducibility Initiatives underline core challenges

  2017cited by this paper
• On the usefulness of useless knowledge

  2017cited by this paper
• Factors Affecting the Survival of SMEs: A Study of Biotechnology Firms in South Korea

  2017cited by this paper
• The revolution re-visited: Clinical and genetics research paradigms and the productivity paradox in drug discovery

  2016cited by this paper
• A pill too hard to swallow: how the NHS is limiting access to high priced drugs

  2016cited by this paper
• Stem cell therapy for Alzheimer's disease: hope or hype?

  2016cited by this paper
• The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses.

  2016cited by this paper
• Big Data and Analytics—A Journey Through Basic Concepts to Research Issues

  2016cited by this paper
• Could a Neuroscientist Understand a Microprocessor?

  2016cited by this paper
• Problems, challenges and promises: perspectives on precision medicine

  2016cited by this paper
• Never Waste a Good Crisis: Confronting Reproducibility in Translational Research.

  2016cited by this paper
• The Use of Superlatives in Cancer Research.

  2016cited by this paper
• Gene name errors are widespread in the scientific literature

  2016cited by this paper
• Estimating the biotech sector's contribution to the US economy

  2016cited by this paper
• American Healthcare: A Profile in Shortages.

  2016cited by this paper
• Good drugs, good intentions, and the (bumpy) road to development

  2016cited by this paper
• The natural selection of bad science

  2016cited by this paper
• When biotech goes bad

  2016cited by this paper
• Cancer moonshot countdown

  2016cited by this paper
• Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the American College of Physicians.

  2016cited by this paper
• White House wants $1 billion for Vice President Biden’s cancer moonshot. Where will it come from?

  2016cited by this paper
• When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis

  2016cited by this paper
• Hate journal impact factors? New study gives you one more reason

  2016cited by this paper
• Making sense of big data in health research: Towards an EU action plan

  2016cited by this paper
• The Diagnosis and Treatment of Alzheimer’s: Are We Being (Ir)responsible?

  2016cited by this paper
• Irreproducibility in Preclinical Biomedical Research: Perceptions, Uncertainties, and Knowledge Gaps.

  2016cited by this paper
• The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

  2016cited by this paper
• Institute for Clinical and Economic Review (ICER) VS. Health Technology Assessment (HTA) Agencies: The Case of Multiple Myeloma and PCSK9S

  2016cited by this paper
• Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling.

  2016cited by this paper
• A U.S. “Cancer Moonshot” to accelerate cancer research

  2016cited by this paper
• Busting the billion-dollar myth: how to slash the cost of drug development

  2016cited by this paper
• Scientists worry as cancer moonshots multiply

  2016cited by this paper
• The chips are down for Moore’s law

  2016cited by this paper
• BIOMEDICAL RESOURCES. Funding for key data resources in jeopardy.

  2016cited by this paper
• A Framework for Improving the Quality of Research in the Biological Sciences

  2016cited by this paper
• Journal of Health Economics

  2016cited by this paper
• Accelerating global innovation to address antibacterial resistance: introducing CARB-X

  2016cited by this paper
• Unknown unknowns in biomedical research: does an inability to deal with ambiguity contribute to issues of irreproducibility?

  2015cited by this paper
• Closing the barn door: Coping with findings of research misconduct by trainees in the biomedical sciences

  2015cited by this paper
• When the East Meets the West:the Future of Traditional Chinese Medicine in the 21st Century

  2015cited by this paper
• Offline: What is medicine's 5 sigma?

  2015cited by this paper
• Reproducibility in Science: Improving the Standard for Basic and Preclinical Research

  2015cited by this paper
• Robust research: Institutions must do their part for reproducibility

  2015cited by this paper
• The Economics of Reproducibility in Preclinical Research

  2015cited by this paper
• (A)Historical Science

  2015cited by this paper
• Meta-research: Evaluation and Improvement of Research Methods and Practices

  2015cited by this paper
• Philanthropy's role in translating scientific innovation

  2015cited by this paper
• The digital revolution in phenotyping

  2015cited by this paper
• Are the Biomedical Sciences Sliding Toward Institutional Corruption? And Why Didn't We Notice It?

  2015cited by this paper
• Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

  2015cited by this paper
• Global, regional, and national incidence, prevalence, and YLDs for 301 acute and chronic diseases and injuries for 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

  2015cited by this paper
• Are scientists a workforce? – Or, how Dr. Frankenstein made biomedical research sick

  2015cited by this paper
• Decline in economic returns from new drugs raises questions about sustaining innovations.

  2015cited by this paper
• Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research

  2015cited by this paper
• Rescuing US biomedical research from its systemic flaws

  2014cited by this paper
• Putting big data to good use in neuroscience

  2014cited by this paper
• How to Make More Published Research True

  2014cited by this paper
• Big data in biomedicine.

  2014cited by this paper
• Restoring the pharmaceutical industry's reputation

  2014cited by this paper
• The association between exaggeration in health related science news and academic press releases: retrospective observational study

  2014cited by this paper
• High cancer drug prices in the United States: reasons and proposed solutions.

  2014cited by this paper
• Coming full circle-from endless complexity to simplicity and back again.

  2014cited by this paper
• Causes for the Persistence of Impact Factor Mania

  2014cited by this paper
• RNA design rules from a massive open laboratory

  2014cited by this paper
• Sticker shock and the price of new therapies for hepatitis C: Is it worth it?

  2014cited by this paper
• Sovaldi makes blockbuster history, ignites drug pricing unrest

  2014cited by this paper
• Intersection of Systematic Review Methodology with the NIH Reproducibility Initiative

  2014cited by this paper
• Scientific rigor through videogames.

  2014cited by this paper
• Benchmarking biotech and pharmaceutical product development

  2014cited by this paper
• The fall and rise of pharmacology--(re-)defining the discipline?

  2014cited by this paper
• The National Institutes of Health's Big Data to Knowledge (BD2K) initiative: capitalizing on biomedical big data

  2014cited by this paper
• Modeling and research on research.

  2014cited by this paper
• Revisiting “Is the scientific paper a fraud?”

  2014cited by this paper
• How Academia Resembles a Drug Gang

  2014cited by this paper
• Mentorship matters for the biomedical workforce

  2014cited by this paper
• Editorial: Do you see what I see? Quality, reliability, and reproducibility in biomedical research.

  2014cited by this paper
• Is the Nobel Prize good for science?

  2013cited by this paper
• Ocean science: Arctic sea ice needs better forecasts

  2013cited by this paper
• NIH mulls rules for validating key results

  2013cited by this paper
• Pharmaceutical innovation and public policy: The case for a new strategy for drug discovery and development

  2013cited by this paper
• Preventing Regulatory Capture: Corrosive Capture? The Dueling Forces of Autonomy and Industry Influence in FDA Pharmaceutical Regulation

  2013cited by this paper
• Multiple Breast Cancer Cell-Lines Derived from a Single Tumor Differ in Their Molecular Characteristics and Tumorigenic Potential

  2013cited by this paper
• Cancer drugs in the United States: Justum Pretium--the just price.

  2013cited by this paper
• How and why US health care differs from that in other OECD countries.

  2013cited by this paper
• Hypothesis-generating research and predictive medicine

  2013cited by this paper
• Sofosbuvir for previously untreated chronic hepatitis C infection.

  2013cited by this paper
• Perspective: Research Misconduct The Search for a Remedy

  2012cited by this paper
• Diagnosing the decline in pharmaceutical R&D efficiency

  2012cited by this paper
• Human mortality improvement in evolutionary context

  2012cited by this paper
• Drug development: Raise standards for preclinical cancer research

  2012cited by this paper
• Saving Money or Just Saving Lives? Improving the Productivity of US Health Care Spending.

  2012cited by this paper
• Iceberg Alert for NIH

  2012cited by this paper
• Rethinking Clinical Trials

  2011cited by this paper
• Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?

  2011cited by this paper
• Crystal structure of a monomeric retroviral protease solved by protein folding game players

  2011cited by this paper
• Demythologizing the high costs of pharmaceutical research

  2011cited by this paper
• Believe it or not: how much can we rely on published data on potential drug targets?

  2011cited by this paper

• A scoping review on what constitutes a good research culture

  2024cites this paper
• Reagent Validation to Facilitate Experimental Reproducibility

  2018cites this paper
• Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics.

  2018cites this paper